Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05887271
Other study ID # 0861
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 29, 2023
Est. completion date January 1, 2026

Study information

Verified date May 2023
Source University of Leicester
Contact Joanna M Bilak, BMBS
Phone +44 (0)116 258 3038
Email jmb99@leicester.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heart failure with preserved ejection fraction (HFpEF) is a common and serious complication of obesity and type 2 diabetes (T2D). HFpEF occurs when the heart muscle unable to relax efficiently to pump the blood around the body. This leads to fluid build-up, breathlessness and inability to tolerate physical exertion. People who develop HFpEF do less well because treatment options are limited. Pilot data in patients with obesity and diabetes and a small number of patients with HFpEF have shown improvements in exercise capacity and reversal of changes in the heart and blood vessels. This study will assess if this is achievable in a multi-ethnic cohort of patients with established HFpEF. A total of 102 adults will be invited and allocate by chance into two groups: either a 12-week diet or health advice on how to lose weight. The study will determine if weight loss over 12 weeks can improve heart function, symptoms and ability to exercise. Additionally, participants' views on changing their diet and how this has impacted their symptoms will be sought during the study in an optional interview. This will help guide treatments planning in the future to get maximum benefits, and to individualize support to patients from different cultural backgrounds.


Description:

Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogenous syndrome, typified by severe exercise intolerance and with limited treatment options. Weight loss achieved through a low energy meal-replacement plan (MRP) has been shown to lead to reversal of cardiovascular remodelling in ethnically diverse asymptomatic adults with pre-HFpEF and HFpEF. This trial will translate this experience with the pragmatic low energy MRP into a symptomatic, multi-ethnic cohort of obese HFpEF, across three sites (Leicester, Manchester and Oxford) to assess its efficacy in improving exercise intolerance, symptoms, quality of life, cardiovascular remodelling, and skeletal myopathy.


Recruitment information / eligibility

Status Recruiting
Enrollment 102
Est. completion date January 1, 2026
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Established clinical diagnosis of heart failure with preserved ejection fraction HFpEF (EF>45%) made by a cardiologist or a primary care physician with heart failure expertise, or a heart failure nurse 2. Clinically stable for = 3 months (no admissions to hospital) 3. Obesity (BMI =30kg/m2 if white European or =27kg/m2 if Asian, Middle Eastern or Black ethnicity) 4. Age =18 Exclusion Criteria: 1. Inability to walk/undertake 6-minute walk test 2. Inability to follow a low-energy MRP 3. HFpEF due to infiltrative cardiomyopathy (cardiac amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy, restrictive cardiomyopathy/pericardial disease or congenital heart disease95 4. Known heritable, idiopathic or drug-induced pulmonary arterial hypertension 5. Severe chronic obstructive pulmonary disease (FEV1< 1.0L) 6. Severe primary valvular heart disease 7. Anaemia (Hb<100g/L) 8. Severe renal disease (eGFR < 30 ml/min/1.73 m2) 9. Weight loss > 5kg in preceding 3 months. 10. Known gallstones/previous biliary colic

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Low calorie meal replacement plan
Meal replacement diet containing ~850 kcal/day (40% protein, 50% carbohydrate, 10% fat) supplied by Counterweight® (www.counterweight.org).The meal replacement plan will comprise of 3-4 meal packs/day (to equate to 850 kcal) with sweet and savoury options, and an allowance of 100ml semi-skimmed milk or a non-dairy alternative.
Diagnostic Test:
Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy
CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum. DIXON technique for the quantification of visceral adiposity and subcutaneous adipose tissue. Cardiac 31P magnetic resonance spectroscopy imaging to assess cardiac muscle energetics according to a standardised operating procedure
Transthoracic echocardiography
Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function
Blood test
Collection of blood samples from each participant to characterise the participant's health status and fibroinflammatory markers.
Electrocardiogram
An ECG will be obtained to assess for baseline rhythm.
Accelerometery
Accelerometer (GeneActiv) measured daily activity levels continuously for 7 consecutive days.
6 minute walk test (6MWT)
Supervised 6MWT will be performed with symptom assessment using dyspnoea scale (Borg's).
Skeletal muscle strength using handgrip strength and quadriceps (Cybex dynamometer)
Skeletal muscle strength will be measured using a cybex dynamometer.
Other:
Assessment of quality of life and heart failure symptoms
Quality of life and HF symptoms will be assessed using the Minnesota Living with Heart Failure (MLWHF) questionnaire, which is used as a standardised measure of self-reported health status, and HF symptoms and is considered to have a good discriminatory power and validity
Assessment of sarcopenia
Participants will be assessed for presence of sarcopenia using the Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls (SARC-F) questionnaire. It is a robust tool for diagnosis of sarcopenia and prediction poor physical function, with excellent specificity in multimorbid individuals.
Assessment of frailty
Frailty will be assessed using the Edmonton Frail Scale (EFS). The EFS is a multidimensional frailty assessment which assesses multiple domains of frailty including functional independence, social support, cognition, medication use, and mood.
Qualitative interview
Participants in the MRP and control groups will be invited to attend a focused semi-structured, 1-2-1 interview aimed to elicit barriers and enablers to the MRP and describe their perspective on the relationship between healthy eating and health interview during the 12-week visit. Participants who complete or drop out will be eligible. Inclusion of participants in the control arm will allow us to compare the experiences of MRP versus health coaching and detect any specific issues people face when trying to introduce lifestyle changes themselves.
Diagnostic Test:
Skeletal muscle magnetic resonance spectroscopy
Assessment of skeletal muscle volume (quadriceps and calf muscle) using MRI, and 31P-magnetic resonance spectroscopy (31P-MRS) of the skeletal muscle using fysiometer and during isometric exercise at rest and after 5 minutes of exercise to assess changes in muscle energetics at rest and on exercise.

Locations

Country Name City State
United Kingdom University of Leicester, Glenfield Hospital, Groby Road Leicester Leicestershire
United Kingdom University of Manchester, Wythenshawe Hospital, Southmoor Road Manchester
United Kingdom University of Oxford, John Radcliffe Hospital, Headley Way Oxford

Sponsors (3)

Lead Sponsor Collaborator
University of Leicester University of Manchester, University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the distance walked during 6 minute walk test (6MWT) The primary outcome measure is a change in the distance walked on 6MWT measured in meters Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Beneficial reverse cardiovascular remodelling CMR-derived measures of cardiovascular remodelling defined as left ventricular mass/volume ratio Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Change in physical activity levels Improvement in physical activity will be determined by change in daily activity as determined accelerometery Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Change in lower limb muscle power Change in muscle power will be determined by quadriceps strength measured using Cybex dynanometer Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Change in upper limb muscle power Change in muscle power will be determined by handgrip strength using fysiometer Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Improvement in exercise tolerance This will be assessed by a)change in Borg dyspnoea scale during 6MWT Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Improvement in symptoms of heart failure This will be assessed by a change in the Minessota Living with Heart failure score Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Change in frailty This will be assessed by a change in the Edmonton frailty questionnaire score Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Change in sarcopenia This will be assessed by a change in the SARC-F questionnaire score Assessed at baseline and 12 weeks, optional repeat at 24 weeks
Secondary Exploratory outcome: Improving skeletal and cardiac energetics 31P magnetic resonance spectroscopy: Cardiac PCr/ATP Baseline and 12 weeks
Secondary Exploratory outcome: change in fibroinflammatory biomarker panel Exploratory analysis of the O-link fibroinflammatory biomarker panel to identify potential pathways involved in the development, progression or outcomes of HFpEF. This will be evaluated at baseline and at 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2